{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:06:06Z","timestamp":1778814366636,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1038\/nm1632","type":"journal-article","created":{"date-parts":[[2007,9,2]],"date-time":"2007-09-02T18:11:26Z","timestamp":1188756686000},"page":"1102-1107","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":879,"title":["Activation of mGlu2\/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial"],"prefix":"10.1038","volume":"13","author":[{"given":"Sandeep T","family":"Patil","sequence":"first","affiliation":[]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[]},{"given":"Ferenc","family":"Martenyi","sequence":"additional","affiliation":[]},{"given":"Stephen L","family":"Lowe","sequence":"additional","affiliation":[]},{"given":"Kimberley A","family":"Jackson","sequence":"additional","affiliation":[]},{"given":"Boris V","family":"Andreev","sequence":"additional","affiliation":[]},{"given":"Alla S","family":"Avedisova","sequence":"additional","affiliation":[]},{"given":"Leonid M","family":"Bardenstein","sequence":"additional","affiliation":[]},{"given":"Issak Y","family":"Gurovich","sequence":"additional","affiliation":[]},{"given":"Margarita A","family":"Morozova","sequence":"additional","affiliation":[]},{"given":"Sergey N","family":"Mosolov","sequence":"additional","affiliation":[]},{"given":"Nikolai G","family":"Neznanov","sequence":"additional","affiliation":[]},{"given":"Alexander M","family":"Reznik","sequence":"additional","affiliation":[]},{"given":"Anatoly B","family":"Smulevich","sequence":"additional","affiliation":[]},{"given":"Vladimir A","family":"Tochilov","sequence":"additional","affiliation":[]},{"given":"Bryan G","family":"Johnson","sequence":"additional","affiliation":[]},{"given":"James A","family":"Monn","sequence":"additional","affiliation":[]},{"given":"Darryle D","family":"Schoepp","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2007,9,2]]},"reference":[{"key":"BFnm1632_CR1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/schbul\/19.2.199","volume":"19","author":"NC Andreasen","year":"1993","unstructured":"Andreasen, N.C. & Carpenter, W.T., Jr. Diagnosis and classification of schizophrenia. Schizophr. Bull. 19, 199\u2013214 (1993).","journal-title":"Schizophr. Bull."},{"key":"BFnm1632_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/00004850-199605002-00012","volume":"11","author":"CA Tamminga","year":"1996","unstructured":"Tamminga, C.A. & Lahti, A.C. The new generation of antipsychotic drugs. Int. Clin. Psychopharmacol. 11, 73\u201376 (1996).","journal-title":"Int. Clin. Psychopharmacol."},{"key":"BFnm1632_CR3","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1124\/jpet.106.110809","volume":"321","author":"LM Rorick-Kehn","year":"2007","unstructured":"Rorick-Kehn, L.M. et al. Pharmacological and pharmacokinetic properties of a structurally-novel, potent, selective mGlu2\/3 receptor agonist: in vitro characterization of LY404039. J. Pharmacol. Exp. Ther. 321, 308\u2013317 (2007).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnm1632_CR4","doi-asserted-by":"crossref","unstructured":"Moghaddam, B. & Adams, B.W. Reversal of phenylcyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281, 1349\u20131352.","DOI":"10.1126\/science.281.5381.1349"},{"key":"BFnm1632_CR5","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0022-3565(24)29296-X","volume":"299","author":"DD Schoepp","year":"2001","unstructured":"Schoepp, D.D. Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J. Pharmacol. Exp. Ther. 299, 12\u201320 (2001).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnm1632_CR6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00213-005-0020-9","volume":"181","author":"CH Large","year":"2005","unstructured":"Large, C.H., Webster, E.L. & Goff, D.C. The potential role of lamotrigine in schizophrenia. Psychopharmacology (Berl.) 181, 415\u2013436 (2005).","journal-title":"Psychopharmacology (Berl.)"},{"key":"BFnm1632_CR7","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.biopsych.2004.06.029","volume":"56","author":"I Kremer","year":"2004","unstructured":"Kremer, I. et al. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol. Psychiatry 56, 441\u2013446 (2004).","journal-title":"Biol. Psychiatry"},{"key":"BFnm1632_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.schres.2004.05.005","volume":"72","author":"HJ Tuominen","year":"2005","unstructured":"Tuominen, H.J., Tiihonen, J. & Wahlbeck, K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr. Res. 72, 225\u2013234 (2005).","journal-title":"Schizophr. Res."},{"key":"BFnm1632_CR9","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s00213-004-2032-2","volume":"179","author":"DC Goff","year":"2005","unstructured":"Goff, D.C. et al. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl.) 179, 144\u2013150 (2005).","journal-title":"Psychopharmacology (Berl.)"},{"key":"BFnm1632_CR10","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.biopsych.2004.12.037","volume":"57","author":"U Heresco-Levy","year":"2005","unstructured":"Heresco-Levy, U. et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol. Psychiatry 57, 577\u2013585 (2005).","journal-title":"Biol. Psychiatry"},{"key":"BFnm1632_CR11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2174\/1568007024606177","volume":"1","author":"DD Schoepp","year":"2002","unstructured":"Schoepp, D.D. & Marek, G.J. Preclinical pharmacology of mGlu2\/3 receptor agonists: novel agents for schizophrenia? Current Drug Targets. CNS & Neurological Disorders. 1, 215\u2013225 (2002).","journal-title":"Current Drug Targets. CNS & Neurological Disorders."},{"key":"BFnm1632_CR12","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1124\/jpet.102.038422","volume":"303","author":"CJ Swanson","year":"2002","unstructured":"Swanson, C.J. & Schoepp, D.D. The group II metabotropic glutamate agonist LY379268 and clozapine reverse phencyclidine-induced behaviors in monoamine-depleted rats. J. Pharmacol. Exp. Ther. 303, 919\u2013927 (2002).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnm1632_CR13","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/S0165-0173(99)00046-6","volume":"31","author":"GK Aghajanian","year":"2000","unstructured":"Aghajanian, G.K. & Marek, G.J. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Research. Brain Res. Brain Res. Rev. 31, 302\u2013312 (2000).","journal-title":"Brain Research. Brain Res. Brain Res. Rev."},{"key":"BFnm1632_CR14","first-page":"819","volume-title":"Neuropsychopharmacology: The Fifth Generation of Progress","author":"HY Meltzer","year":"2002","unstructured":"Meltzer, H.Y. Neuropsychopharmacology: The Fifth Generation of Progress (eds. Davis, K.L., Charney, D., Coyle, J.T. & Nemeroff, C.) 819\u2013831 (Lippincott Williams & Wilkins, 2002)."},{"key":"BFnm1632_CR15","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0022-3565(24)35262-0","volume":"292","author":"GJ Marek","year":"2000","unstructured":"Marek, G.J., Wright, R.A., Schoepp, D.D., Monn, J.A. & Aghajanian, G.K. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. J. Pharmacol. Exp. Ther. 292, 76\u201387 (2000).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnm1632_CR16","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S0028-3908(97)00051-8","volume":"36","author":"GK Aghajanian","year":"1997","unstructured":"Aghajanian, G.K. & Marek, G.J. Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology 36, 589\u2013599 (1997).","journal-title":"Neuropharmacology"},{"key":"BFnm1632_CR17","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0306-4522(01)00199-3","volume":"105","author":"GJ Marek","year":"2001","unstructured":"Marek, G.J., Wright, R.A., Gewirtz, J.C. & Schoepp, D.D. A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex. Neuroscience 105, 379\u2013392 (2001).","journal-title":"Neuroscience"},{"key":"BFnm1632_CR18","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S0893-133X(00)00136-6","volume":"23","author":"JC Gewirtz","year":"2000","unstructured":"Gewirtz, J.C. & Marek, G.J. Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors. Neuropsychopharmacology 23, 569\u2013576 (2000).","journal-title":"Neuropsychopharmacology"},{"key":"BFnm1632_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/sj.npp.1300013","volume":"28","author":"Y Zhai","year":"2003","unstructured":"Zhai, Y. et al. Group II metabotropic glutamate receptor modulation of DOI-induced c-fos mRNA and excitatory responses in the cerebral cortex. Neuropsychopharmacology 28, 45\u201352 (2003).","journal-title":"Neuropsychopharmacology"},{"key":"BFnm1632_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0163-7258(93)90036-D","volume":"57","author":"BA Ellenbroek","year":"1993","unstructured":"Ellenbroek, B.A. Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs. Pharmacol. Ther. 57, 1\u201378 (1993).","journal-title":"Pharmacol. Ther."},{"key":"BFnm1632_CR21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0006-8993(94)90021-3","volume":"643","author":"L Svensson","year":"1994","unstructured":"Svensson, L., Zhang, J., Johannessen, K. & Engel, J.A. Effect of local infusion of glutamate analogues into the nucleus accumbens of rats: an electrochemical and behavioural study. Brain Res. 643, 155\u2013161 (1994).","journal-title":"Brain Res."},{"key":"BFnm1632_CR22","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1124\/jpet.102.039735","volume":"303","author":"ZX Xi","year":"2002","unstructured":"Xi, Z.X. et al. Modulation of group II metabotropic glutamate receptor signaling by chronic cocaine. J. Pharmacol. Exp. Ther. 303, 608\u2013615 (2002).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnm1632_CR23","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0022-3565(24)38151-0","volume":"289","author":"G Hu","year":"1999","unstructured":"Hu, G., Duffy, P., Swanson, C., Ghasemzadeh, M.B. & Kalivas, P.W. The regulation of dopamine transmission by metabotropic glutamate receptors. J. Pharmacol. Exp. Ther. 289, 412\u2013416 (1999).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnm1632_CR24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0022-3565(24)35084-0","volume":"291","author":"J Cartmell","year":"1999","unstructured":"Cartmell, J., Monn, J.A. & Schoepp, D.D. The metabotropic glutamate 2\/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus D-amphetamine motor behaviors in rats. J. Pharmacol. Exp. Ther. 291, 161\u2013170 (1999).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnm1632_CR25","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/978-1-4615-0123-7_7","volume":"513","author":"PJ Flor","year":"2002","unstructured":"Flor, P.J., Battaglia, G., Nicoletti, F., Gasparini, F. & Bruno, V. Neuroprotective activity of metabotropic glutamate receptor ligands. Adv. Exp. Med. Biol. 513, 197\u2013223 (2002).","journal-title":"Adv. Exp. Med. Biol."},{"key":"BFnm1632_CR26","first-page":"11","volume":"382","author":"WW Fleischhacker","year":"1994","unstructured":"Fleischhacker, W.W., Meise, U., Gunther, V. & Kurz, M. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr. Scand. Suppl. 382, 11\u201315 (1994).","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"BFnm1632_CR27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0920-9964(97)00036-4","volume":"26","author":"AM Crawford","year":"1997","unstructured":"Crawford, A.M., Beasley, C.M., Jr. & Tollefson, G.D. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr. Res. 26, 41\u201354 (1997).","journal-title":"Schizophr. Res."},{"key":"BFnm1632_CR28","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/S0028-3908(02)00142-9","volume":"43","author":"MP Johnson","year":"2002","unstructured":"Johnson, M.P. & Chamberlain, M. Modulation of stress-induced and stimulated hyperprolactinemia with the group II metabotropic glutamate receptor selective agonist, LY379268. Neuropharmacology 43, 799\u2013808 (2002).","journal-title":"Neuropharmacology"},{"key":"BFnm1632_CR29","volume-title":"Positive and negative syndrome scale (PANSS) manual","author":"SR Kay","year":"1986","unstructured":"Kay, S.R., Opler, L.A. & Fiszbein, A. Positive and negative syndrome scale (PANSS) manual. (Multi-Health Systems, North Tonawanda, New York, USA, 1986)."},{"key":"BFnm1632_CR30","volume-title":"ECDEU assessment manual for psychopharmacology, revised version","author":"W Guy","year":"1976","unstructured":"Guy, W. ECDEU assessment manual for psychopharmacology, revised version. (US Department of Health, Education and Welfare, Bethesda, Maryland, USA, 1976)."}],"updated-by":[{"DOI":"10.1038\/nm1007-1264","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nm1632.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm1632","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/nm1632","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/nm1632.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T20:23:14Z","timestamp":1737404594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nm1632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["BFnm1632"],"URL":"https:\/\/doi.org\/10.1038\/nm1632","relation":{"erratum":[{"id-type":"doi","id":"10.1038\/nm1007-1264","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9]]},"assertion":[{"value":"5 December 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2007","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Corrigendum","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Nat. Med. 13, 1102-1107 (2007); published online 2 September; corrected after print 17 September 2007. In the version of this article initially published, the affiliation of the name of one person acknowledged was misspelled, and reference 4 should have been: Moghaddam, B. & Adams, B.W. Reversal of phenylcyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281, 1349\u20131352. These errors have been corrected in the HTML and PDF versions of the article.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.T.P., L.Z., F.M., S.L.L., K.A.J., J.A.M., B.G.J., & D.D.S. are\/were employees of Eli Lilly and Company at the time of this clinical study. Several of them own Lilly stock.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}